Vanda Pharmaceuticals, Inc. (VNDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.43+1.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VNDA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 215.7 | 216.1 | 198.8 | 192.6 | 254.4 | 268.7 | 248.2 | 227.2 | 193.1 | 165.1 | 146.0 | 109.9 | 50.2 | 33.9 | 32.7 | 31.3 |
| Total Revenues | 215.7 | 216.1 | 198.8 | 192.6 | 254.4 | 268.7 | 248.2 | 227.2 | 193.1 | 165.1 | 146.0 | 109.9 | 50.2 | 33.9 | 32.7 | 31.3 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 263.5 | 238.0 | 146.4 | 112.9 | 136.5 | 124.0 | 140.5 | 129.7 | 105.8 | 123.8 | 99.8 | 84.5 | 84.6 | — | — | — |
| R&D Expenses | 117.0 | 109.3 | 74.4 | 76.8 | 85.8 | 75.4 | 55.6 | 48.6 | 43.6 | 38.5 | 29.2 | 29.1 | 19.2 | 28.5 | 45.8 | 29.0 |
| Operating Income | (185.7) | (151.2) | (40.7) | (14.0) | 6.3 | 42.2 | 27.2 | 22.8 | 21.7 | (16.9) | (18.6) | (40.2) | 20.1 | (21.2) | (29.2) | (10.7) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.5 |
| EBT, Incl. Unusual Items | (177.2) | (138.6) | (22.9) | 6.3 | 11.3 | 42.4 | 31.7 | 29.0 | 25.3 | (15.4) | (17.9) | — | — | (20.3) | (27.7) | (10.2) |
| Income Tax Expense | 97.7 | 81.8 | (4.0) | 3.8 | 5.0 | 9.2 | 8.3 | (86.5) | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | (0.4) | (0.4) | (0.4) |
| Net Income | ||||||||||||||||
| Net Income | (274.9) | (220.5) | (18.9) | 2.5 | 6.3 | 33.2 | 23.3 | 115.6 | 25.2 | (15.6) | (18.0) | (39.9) | 20.2 | (21.1) | (28.6) | (9.8) |
| Per Share | ||||||||||||||||
| Basic EPS | (4.56) | (3.74) | (0.33) | 0.04 | 0.11 | 0.60 | 0.43 | 2.17 | 0.50 | (0.35) | (0.41) | (0.94) | 0.58 | (0.69) | (1.01) | (0.35) |
| Diluted EPS | (4.56) | (3.74) | (0.33) | 0.04 | 0.11 | 0.58 | 0.42 | 2.11 | 0.48 | (0.35) | (0.41) | (0.94) | 0.55 | (0.69) | (1.01) | (0.35) |
| Revenue per Share | 3.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 60.2 | 58.9 | 58.1 | 57.4 | 56.5 | 55.5 | 54.4 | 53.1 | 50.9 | 44.7 | 43.4 | 42.3 | 34.8 | 30.4 | 28.2 | 28.1 |
| Diluted Weighted Avg Shares | 60.2 | 58.9 | 58.1 | 57.6 | 57.0 | 56.9 | 55.2 | 54.8 | 53.0 | 44.7 | 43.4 | 42.3 | 36.7 | 30.4 | 28.2 | 28.1 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | 20.6 | (20.8) | (28.5) | (10.2) |
| EBIT | (185.7) | (151.2) | (40.7) | (14.0) | 6.3 | 42.2 | 27.2 | 22.8 | 21.7 | (16.9) | (18.6) | (40.2) | 20.1 | (21.2) | (29.2) | (10.7) |
| Effective Tax Rate | -55.1% | — | — | 60.4% | 44.5% | 21.7% | 26.3% | -298.1% | 0.5% | -0.9% | -0.6% | — | — | 2.2% | 1.6% | 4.3% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.